ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0639

Improving Pre-biologic Infection Screening Using a Best Practice Alert in Electronic Health Records

Hailey Baker1, Rebecca Fine1, Betty Hsiao2, Vaidehi Chowdhary3, Lisa Suter4 and Abhijeet Danve5, 1Yale University, New Haven, CT, 2Yale-New Haven Medical Center, New Haven, CT, 3Yale University, East Haven, CT, 4Yale School of Medicine, New Haven, CT, 5Yale University, Rocky Hill, CT

Meeting: ACR Convergence 2021

Keywords: Biologicals, Infection, Quality Indicators, quality of care

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: Measures & Measurement of Healthcare Quality Poster (0623–0659)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Biologics and small molecules (bDMARDs) are important immunomodulatory medications for management of patients with rheumatic diseases. Use of a bDMARD in patients with infection with pre-existing tuberculosis (TB), hepatitis B (HBV), or hepatitis C (HCV) can have serious consequences. Many national and international societies recommend timely screening for one or all of these exposures prior to initiation of certain bDMARDs, however, adherence to these recommendations varies widely. This quality improvement initiative focused on improving compliance with current standards using a best practice advisory (BPA) in the electronic health records (EHR).

Methods: Patients aged 18 years or older with at least two visits with a provider in the section of Rheumatology in the designated time frame were included. Upon a new prescription of a bDMARD, providers were alerted via a BPA pop-up in the EHR about the last available results if any, for TB, HBV, and HCV, and allowed for quick ordering as required. This BPA was implemented starting in December 2020. To assess the impact of the BPA, baseline rates of screening for TB (Quantiferon), HBV, and HCV for patients prescribed a new bDMARD from October 1, 2017 to November 30, 2020 (pre-BPA) were compared with those of patients with prescriptions from December 1, 2020 to April 9, 2021 (post-BPA). Data were collected for various bDMARDs targeting tumor necrosis factor (TNF), interleukin-17 (IL-17), interleukin-6 (IL-6), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), CD20, and Janus kinase (Jak).

Results: A total of 821 patients met the above inclusion criteria with 768 patients pre-BPA and 63 patients post-BPA implementation. The two patient populations were similar in gender, age, race/ethnicity, rheumatic disease diagnosis, and a new bDMARD prescription. Median age of study population was 65 years, 70% were female, majority (77%) were white; most common rheumatic diseases were inflammatory arthritis (88%) and connective tissue disease (7%). TNFi (52%), IL-17 inhibitors (16%) and JAK inhibitors (15%) were most common bDMARDs prescribed. BPA implementation was associated with statistically significant improvement in screening for TB (pre-BPA 68% vs post-BPA 83% p=0.001), HCV (61% vs 83% p=0.0003) and hepatitis B core antibody (HBcAb) (33% vs 57% p=0.00001), numerical improvement in hepatitis B surface antigen (HBsAG) screening (39% vs 43% p=0.44) and no improvement in hepatitis B surface antibody (HBsAb) testing (29% each p=1.0) (Table 1).

Conclusion: Implementation of an electronic BPA in the EHR has the capacity to improve screening rates in patients who are started on a bDMARD. The BPA facilitates rapid review of screening tests and enhances provider experience and efficiency. Limitations include difficulty in capturing laboratory results performed outside the EHR.

Table 1. Comparison of screening rates of TB, HBV, and HCV captured pre-BPA and post-BPA. Displays captured screening rates of TB, HBV, and HCV before and after the initiation of the BPA.

Figure 1. BPA notification. This is a visualization of the best practice advisory that appears on provider screens when ordering a biologic or bDMARD for a patient that does not have up-to-date infection screening within the defined time interval.


Disclosures: H. Baker, None; R. Fine, None; B. Hsiao, None; V. Chowdhary, None; L. Suter, None; A. Danve, Abbvie, 1, Novartis, 5, 6.

To cite this abstract in AMA style:

Baker H, Fine R, Hsiao B, Chowdhary V, Suter L, Danve A. Improving Pre-biologic Infection Screening Using a Best Practice Alert in Electronic Health Records [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/improving-pre-biologic-infection-screening-using-a-best-practice-alert-in-electronic-health-records/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improving-pre-biologic-infection-screening-using-a-best-practice-alert-in-electronic-health-records/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences